EU Study Revives Industry Attacks On Promotion Of Off-Label Use To Save Money
Executive Summary
A study for the European Commission explores in detail the drivers behind off-label use of medicines in EU countries, but the pharmaceutical industry would have liked it to speak out against national authorities’ promotion of off-label uses for economic reasons.
You may also be interested in...
Roche, Novartis Lose French Court Battle Over Off-Label Use Of Avastin In AMD
Roche and Novartis have been unsuccessful in their attempt to stop the French authorities using Avastin off label in wet AMD for financial reasons.
Drug Industry Calls For EU Action Against French Off-Label Law
The European pharmaceutical industry has filed a second complaint with the European Commission against national legislation allowing the off-label use of cheaper medicines where approved alternatives exist, for purely financial reasons1.
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.